Ciglitazone NEW
| Price | $89 |
| Package | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Ciglitazone | CAS No.: 74772-77-3 |
| Purity: 99.84% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Ciglitazone |
| Description | Ciglitazone (ADD 3878) is a potent and selective PPARγ agonist (EC50: 3 μM) and oral hypoglycemic agent. Ciglitazone inhibits proliferation and differentiation of th17 cells, decreases insulin levels, vascular endothelial growth factor production and blood pressure, and induces cell cycle arrest in gastric cancer cells. Selegiline induces apoptosis in opossum kidney epithelial cells and activates nuclear translocation of p38 MAPK and apoptosis-inducing factor (AIF). Ciglitazone exhibits hypoglycaemic activity in animal models of obesity and hyperglycaemia. |
| In vitro | Ciglitazone (0-20 μM ; 24 hours) ciglitazone causes the generation of ROS and an increase in intracellular Ca2+ and induces apoptosis through a PPAR-independent mechanism.[4] |
| In vivo | Ciglitazone (100 mg/kg/day ; 2 days ; C57BL/6J-ob/ob mice) elicits a drastic fall in blood glucose.[3] Ciglitazone (100 mg/kg/day ; 41-44 days ; ob/ob mice) degranulation of islet beta-cells and increased pancreatic insulin content are observed.[3] |
| Storage | Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : < 10 mg/mL (29.99 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (29.99 mM), Solution. 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (9.9 mM), Sonication is recommended. DMSO : 250 mg/mL (749.74 mM), Sonication is recommended. |
| Keywords | U63287 | PPARγ | p38MAPK | p38 MAPK | Ciglitazone | Apoptosis | AIF |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Daidzein | Metronidazole | D-Psicose | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Anti-Colorectal Cancer Compound Library | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Diabetic Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.10 |
VIP6Y
|
Dideu Industries Group Limited
|
2025-11-18 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY